Lidocaine-loaded polylactic acid-poly(ε-caprolactone) nano capsules to improve sustainable drug delivery system for nursing care of pain management

Abstract

In recent years, drug-loaded polymeric nano capsules have demonstrated potential as drug delivery methods. In this work, lidocaine (LID) loaded polylactic acid-poly(ε-caprolactone) (PLA-PCL) nano capsules were prepared to achieve the controlled drug release. The mechanical characteristics of the PLA-PCL nano capsules were examined via rheological analysis. The composite structure of the PLA-PCL nano capsules, which had a size of less than 1 μm, exhibited a smooth surface without cracks or pores. DLS studies were used to assess PLA-PCL nanoparticle solutions in vitro in terms of particle size (87.5 nm), polydispersity (0.42), and zeta potential surface charge (−24.1 mV). The effective development of PLA-PCL nano capsules with desired physicochemical characteristics and a controlled release mechanism. The LID containing PLA-PCL nano capsules exhibited remarkable encapsulation efficiency and drug loading (78.8±1.92% and 7.53±0.75%). Cytotoxicity assays test on Balb-c 3T3 cells confirmed that the LID-loaded PLA-PCL nano capsules reduced its toxicity, relative to the free LID drug. The in vivo results demonstrated that the LID-loaded PLA-PCL nano capsules significantly endorsed healing in mice defects compared to PLA-PCL nano capsules alone. These findings indicate the potential of LID-loaded PLA-PCL nano capsules as sustainable drug delivery systems for pain management in emerging nursing care.